To determine whether hospital volume is associated with clinical and economic outcomes for patients with pancreatic cancer who underwent pancreatic resection, palliative bypass, or endoscopic or percutaneous stent procedures in Maryland between 1990 and 1995.
Summary Background Data
Previous studies have demonstrated that outcomes for patients undergoing a Whipple procedure improve with higher surgical volume, but only 20% to 35% of patients with pancreatic cancer qualify for curative resection. Most patients undergo palliative procedures instead with a surgical bypass or biliary stent.
Methods
Analysis of hospital discharge data from all nonfederal acute care hospitals in Maryland identified all patients with pancreatic cancer who underwent a pancreatic resection, palliative bypass, or stent procedure between 1990 and 1995. Hospitals (n = 48) were categorized as high-, medium-, and lowvolume providers according to their average annual volume of these procedures. Multivariate regression was used to examine the association between hospital volume and in-hospital mortality rate, length of stay, and hospital charges, after adjusting for differences in case mix and surgeon volume.
Results
Increased hospital volume is associated with markedly decreased in-hospital mortality rates and a decreased or similar length of stay for all three types of procedures and with decreased or similar hospital charges for resections and stents. After adjustment for case mix differences, the relative risk (RR) of in-hospital death after pancreatic resection was 19. 3 and 8 at the low-and medium-volume hospitals, respectively, versus the high-volume hospital; after bypasses, the RR of death was 2.7 and 1.9, respectively; and after stents, the RR was 4.3 and 4.8, respectively.
Conclusions
Patients with pancreatic cancer who are to be treated with curative or palliative procedures appear to benefit from referral to a high-volume provider.
In the present cost-conscious health care environment, there is considerable interest among health care policy makers and payers concerning the regional referral of patients to hospitals that have special expertise in a given procedure.1 2 comes for pancreatic resection by either pancreaticoduodenectomy or total pancreatectomy to offer patients the potential for cure.8 However, resection is possible in only 20% to 35% of patients with pancreatic cancer. Therefore, palliation to relieve symptoms of obstructive jaundice, gastric outlet obstruction, and pain is of primary importance in most patients.9-11 Like resection, palliation of pancreatic cancer involves complex surgical and nonsurgical procedures, including biliary bypass, gastrojejunostomy, endoscopic and percutaneous biliary stenting, and chemical splanchnicectomy.9-11 These procedures may be technically difficult to perform and can be associated with substantial complications, often because of the advanced extent of disease in many patients.
Although significant progress has been made in recent years in the management of pancreatic cancer, less than 20% of all patients diagnosed with the disease survive 1 year, and the overall 5-year survival is less than 5%. 12 Therefore, short-term clinical and economic outcomes are especially important in the setting of a disease such as pancreatic cancer where life expectancy is short. If referral patterns are to be implemented based on outcomes, consideration must be given to the management of the entire spectrum of disease and include evaluation of treatment strategies for both resectable and unresectable tumors. This analysis was performed to determine whether increased hospital volume was associated with a decreased in-hospital mortality rate, a shortened length of stay, and decreased hospital charges for patients undergoing palliative procedures as well as curative surgery for pancreatic cancer.
METHODS

Hospital and Patient Characteristics
A cross-sectional analysis was performed of hospital discharge data from 48 nonfederal acute care hospitals in Maryland collected by the Maryland Health Services Cost Review Commission (HSCRC). These publicly available data were used to identify all patients with a primary or secondary diagnosis of pancreatic cancer (International Classification of Diseases [ICD-9] diagnosis code 157.x) who underwent a primary procedure that was an attempt at curative resection, a gastrointestinal or biliary-enteric bypass, or endoscopic or percutaneous stent placement between January 1990 and December 1995. For our analyses, three broad procedure categories were created:
. The pancreatic resections group included pancreaticoduodenectomy (ICD-9 code 52.7) and total pancreatectomy (ICD-9 code 52.6 An alternative set of analyses was performed whereby patients who died in the hospital were excluded. We also performed a secondary analysis of how hospital volume was related to outcomes by using an alternative method of categorizing hospital volume in which three high-volume providers accounted for approximately 52% of all pancreatic cancer cases (range 53 to 528 cases during the entire study period), 15 medium-volume providers for 25% of cases (range 15 to 41 cases), and 29 low-volume providers for 23% of cases (range 1 to 14 cases).
Patient Outcomes
The outcomes of interest were in-hospital case fatality (referred to as in-hospital mortality rate), mean total hospital length of stay, and mean total hospital charges. Hospital charges were adjusted for inflation based on the appropriate The distributions of patient characteristics among provider groups were compared using analysis of variance for the continuous variables (age and comorbidity score) and the chi-square statistic for categorical variables. Bivariate analyses were used to determine which variables were associated with outcomes. Based on these analyses, we determined which variables to adjust for in the multivariate regression models.
Multiple linear regression was used to assess how length of stay and charges differed between hospital groups after adjusting for patient age, gender, race, number of comorbidities, and urgency of admission. Separate analyses were performed for each of the three procedure categories. Because mean length of stay and mean total charge data were skewed to the right, a natural log transformation was performed to achieve a more normal distribution. To estimate the adjusted length of stay and average total charges for each group, we transformed the data back to their original scales by exponentiating the values predicted by the models.
Poisson regression was used to model the relative risk of in-hospital death between hospital groups, adjusting for case mix. This regression technique often is used when event rates (i.e., mortality) are low.
All statistical inferences pertaining to mean length of stay and hospital charges are based on the log-transformed data. Probability values greater than 0.05 are reported as nonsig- 
RESULTS
In-Hospital Mortality Rate
The unadjusted in-hospital mortality rates were lower at the high-volume provider than at the medium-and lowvolume providers across all three procedures (Fig. 2) . Inhospital mortality rates for patients undergoing pancreatic resections were 0.9%, 6 .9%, and 18.8% at the high-, medium-, and low-volume providers, respectively; for patients undergoing bypasses, they were 4.2%, 10.5%, and 15.3%, respectively; and for patients who received stents, they were 1.6%, 10.9%, and 9.8%, respectively. Differences were statistically significant for pancreatic resections and bypasses. The consistency of the stepwise inverse relation between volume and in-hospital death for resections and bypasses is notable.
Adjustments were made for differences in patient age, gender, race, comorbidity score, and urgency of admission between groups. Patients who underwent a resection had a 19.3 (95% confidence interval [CI] 5.5-68.1) times greater risk of in-hospital death at low-volume providers and an 8 (CI 1.9-34.0) times greater risk of death at medium-volume providers than at the high-volume provider ( Table 2 ). Patients who underwent bypasses had a 2.7 (CI 1.1-6.6) and a 1.9 (CI 0.7-5) times greater risk of death at the lowvolume and medium-volume providers, respectively, than at the high-volume provider. Patients who had a stent placed had a 4.3 (CI 0.5-35.3) and 4.8 (CI 0.6-42.3) times greater risk of in-hospital death at low-volume and medium-volume providers, respectively, than at the high-volume provider.
Length of Stay
Unadjusted mean length of stay was consistently the lowest at the high-volume provider across procedure categories, and the differences were statistically significant. For pancreatic resections, length of stay at the high-, medium-, and low-volume providers was 18.2, 21.1, and 23.6 days, respectively (p < 0.001); for bypasses, it was 15.1, 17.2, and 19.6 days, respectively (p < 0.001); and for stents, it was 7.6, 8.6, and 11.4 days, respectively (p = 0.04).
The pattern remained after adjusting for differences in patient age, gender, race, comorbidity score, and urgency of admission between groups (Fig. 3) 
Hospital Charges
Differences in mean total hospital charges by hospital volume were less consistent (Fig. 4) . Hospital charges for pancreatic resections were lowest at the high-volume provider ($22,379 vs. $26,053 and $33,249 at medium-and low-volume providers, respectively), and these differences were statistically significant (p < 0.001). Hospital charges for palliative bypasses were lowest at medium-volume providers ($15,654 vs. $17,377 and $17,483 at the high-and low-volume providers, respectively), but only the difference with low-volume providers was statistically significant (p = 0.04). Charges for stents were lowest at high-volume providers ($8373 vs. $9760 and $9564 at the medium-and low-volume providers, respectively), but the differences were not significant. Examination of specific hospital charges (i.e., routine, operating room, supplies, laboratories, radiology, drugs, and therapy) did not identify a consistent source for the differences in charges.
After adjusting for patient age, gender, race, comorbidity score, and urgency of admission, different patterns emerged. Hospital charges for pancreatic resections were significantly lower (p < 0.001) at the high-volume provider than at low-volume providers ($20,186 vs. $26,455); they were also lower than at medium-volume providers ($22,217), but this difference was not significant. Adjusted hospital charges for palliative bypasses were slightly higher at the high-volume provider than at medium-and lowvolume providers ($16,153 vs. $12,761 and $14,463, respectively), but only the difference between the mediumvolume providers and the high-volume provider was significant (p < 0.001). For stents, adjusted charges at the high-volume provider were slightly less than at the mediumand low-volume providers ($5641 vs. $6828 and $6649, respectively), but the differences were not significant. Ad Analyses were performed examining the potential independent effect on outcomes of the volume of pancreatic cancer surgery performed by individual surgeons. Concurrent modeling of both hospital and surgeon volume revealed that the influence on outcomes was exerted mainly by hospital volume. As shown in Table 3 , unadjusted in-hospital mortality rates for all pancreatic cancer procedures increased as hospital volume decreased, even when the data were stratified by individual surgeon volume. In contrast, there was no consistent difference in the in-hospital mortality rate related to an individual surgeon's volume of procedures. These patterns also were seen for length of stay (Table 4 ). There was no evidence of consistent interaction between surgeon volume and hospital volume.
The findings regarding differences between hospital groups in in-hospital mortality rate, length of stay, and hospital charges were not changed when we included patient insurance status, place of residence, and time period. Removing in-hospital deaths from the analysis of length of stay and total charges had no effect on our conclusions about differences related to hospital volume. In addition, when we used a different categorization of hospital volume in which the three highest-volume hospitals were included in the high-volume group, the models yielded similar results, although the highest-volume hospital's effects were dampened.
DISCUSSION
Pancreatic cancer is the fifth leading cause of cancer death in the United States, and approximately 28,000 people die of the disease each year.10 Although pancreatic cancer continues to have a poor prognosis, advances in the last decade have led to a better understanding of its molecular genetics and improvements in its management.'8 Currently, more patients with pancreatic cancer undergo procedures with curative and palliative intent, magnifying the implications for health care costs and quality of care.
Based on the analysis presented here, it appears that increased hospital volume is associated with a markedly decreased in-hospital mortality rate for both curative surgery and palliative procedures in patients with pancreatic cancer. This finding is more pronounced for pancreatic resections than for palliative procedures. The decreased mortality rate at the high-volume provider is associated with a decreased or similar length of stay than at the mediumand low-volume providers for all procedures, and with decreased or similar hospital charges for resections and stents.
The results of this analysis support earlier studies linking better outcomes with greater volume of cases;7"19-2 this analysis also extends the findings of studies that have shown an association between increased hospital volume and better outcomes for pancreaticoduodenectomy.3-6 It is not just volume of patients per se that is associated with improved performance,16 but volume of similar types of patients-in this case, patients with pancreatic cancer. Some of the previous studies that examined the relation between volume and outcomes from pancreaticoduodenectomy did not take into consideration the diagnosis of pancreatic cancer.3 '4'22 Further, the current study includes patients with pancreatic cancer undergoing resection as well as the majority of patients who do not qualify for resection but who benefit from palliative procedures for their advanced disease.
Having more experience with similar types of patients might be associated with improved performance for a number of reasons. High-volume centers may be more likely than low-volume centers to develop a systematic approach and organizational routines for handling such patients by developing critical pathways and involving case managers. This, in turn, may enhance the performance of all partici- pants in the health care delivery team. Specialized facilities and equipment may be more likely to be on hand to support diagnosis and therapy as the flow of patients becomes larger. The association between increased volume and improved outcomes across all three procedures suggests that there is a significant hospital system effect. By including in our analysis stents (placed percutaneously by invasive radiologists or endoscopically by gastroenterologists), bypasses (performed by general surgeons), and pancreaticoduodenectomies (usually performed by surgeons concentrating in gastrointestinal surgery), we studied health care providers dealina with patients with pancreatic cancer across several specialties. Our data suggest that the combined "experience effect" of the whole team of pancreatic cancer care providers at a hospital may be more important than the number of operations performed by a particular surgeon. Hospital volume had the strongest and most consistent association with outcomes among the variables included in our data set. It is possible that a large experienced surgical team, specialized nurses, intensivists, anesthesiologists, radiologists, and hospital monitoring procedures are of paramount importance for complex, high-risk procedures performed in patients with a highly morbid disease such as pancreatic cancer. Our findings should be qualified, however, because the distribution of patients by individual surgeon volume was somewhat skewed, with all the high-volume pancreatic surgeons working at the highest-volume hospital. We could not assess the outcomes for high-volume surgeons at mediumand low-volume hospitals, but low-volume surgeons at high-volume hospitals had outcomes similar to those of the high-volume surgeons, whereas low-volume surgeons at low-volume hospitals tended to have the worst outcomes.
An alternative explanation for the association between increased hospital volume and improved outcomes is that low-volume providers treat sicker patients, with a resulting higher mortality rate. Although our data indicate that lowvolume providers tend toward having patients with a higher surgical risk (e.g., older with greater comorbidity), the magnitude and statistical significance of the difference in mortality rates between high-and low-volume groups were essentially unchanged by our adjustment for We are also totally against preoperative pancreatic biopsies in order to obtain a tissue diagnosis. So certainly if those patients get into our hands in an earlier state, they can get a spiral CT or possibly an MRCP, and probably learn all the data we need to know with one procedure; therefore, avoiding a lot of other costs and potentially morbid procedures.
DR. JOHN M. HOWARD (Toledo, Ohio): About 30 years ago I presented a paper to this organization which in essence said the
